Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344669 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL344670 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL10585294 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL12585497 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943562 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL4370045 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943561 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL5870038 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300984 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300985 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| US-5733906-A | Inhibitors of HIV Protease useful for the treatment of Aids | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0604184-B1 | Inhibitors of HIV protease useful for the treatment of aids | LILLY CO ELI (US) | 1997-07-09 | — | — | EP | disclosed |
| EP-0604186-B1 | Inhibitors of HIV protease useful for the treatment of aids | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5554653-A | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| US-5491166-A | ENZYME INHIBITORS, VIRICIDES | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0652009-A1 | Identification and use of protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604184-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604185-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993017701-A1 | ENDOTHELIN RECEPTOR-BINDING PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | PPARA 3022/4885KLK5 2614/4885KLK7 2208/4885 |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | PPARA 196/4885KLK5 3013/4885KLK7 4015/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 1689/4885KLK5 4100/4885KLK7 4265/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | PPARA 3022/4885KLK5 2614/4885KLK7 2208/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 2117/4885KLK5 4189/4885KLK7 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.